Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer
HER2 loss and decrease in HER2 expression are common in patients with MBC receiving treatment with T-DXd. Reevaluation of HER2 status following T-DXd treatment should be considered prior to alternate HER2-targeted therapies that require HER2 overexpression for efficacy.
Authors
- Senthil Damodaran (ORCID: https://orcid.org/0000-0002-2470-0891)
- Paula Raffin Pohlmann (ORCID: https://orcid.org/0000-0001-7914-5162)
- Sarina A. Piha‐Paul (ORCID: https://orcid.org/0000-0001-9455-1660)
- Rashmi K. Murthy (ORCID: https://orcid.org/0000-0002-0103-4718)
- Jordi Rodón (ORCID: https://orcid.org/0000-0001-6467-3632)
- Jason Aboudi Mouabbi (ORCID: https://orcid.org/0000-0001-8689-6845)
- Ayşegül A. Şahin (ORCID: https://orcid.org/0000-0001-8259-9624)
- Amrit S. Gonugunta (ORCID: https://orcid.org/0000-0002-1666-9871)
- Timothy Anthony Yap (ORCID: https://orcid.org/0000-0002-2154-3309)
- Mohamed A. Gouda (ORCID: https://orcid.org/0000-0003-4829-6739)
- Funda Meric‐Bernstam (ORCID: https://orcid.org/0000-0001-6816-6072)
- Vicente Valero (ORCID: https://orcid.org/0000-0001-5913-7480)
- Hui Chen (ORCID: https://orcid.org/0000-0002-5847-0561)
- Debu Tripathy (ORCID: https://orcid.org/0000-0002-5711-2404)
- Ecaterina E Ileana Dumbrava (ORCID: https://orcid.org/0000-0002-1959-0536)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- The University of Texas Health Science Center (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-01-22
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-3468
- Citations
- 12
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 12.54